Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma

This study is testing an experimental treatment for relapsed or treatment-resistant B-cell lymphoma (a type of blood cancer), where a modified virus is engineered to deliver instructions inside the body to create cancer-fighting immune cells (called CAR-T or CAR-M cells) that specifically target CD19, a protein on cancer cells. Unlike standard CAR-T therapy where cells are removed and engineered outside the body, this approach tries to trigger the process inside the patient. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed diagnosis of B-cell non-Hodgkin lymphoma (including DLBCL, mantle cell lymphoma, or similar subtypes) that is CD19-positive - Your lymphoma has come back or stopped responding after at least 2 prior lines of treatment - You are in reasonably good physical health (ECOG 0–2) **You may NOT be eligible if...** - You have central nervous system lymphoma - You have had an organ transplant - You have active HIV, hepatitis, or serious infections - You are allergic to eggs or albumin - You are pregnant or breastfeeding - You have received smallpox vaccination within 3 months Talk to your doctor to see if this trial is right for you.